Trusted veterinary advice and products
This product requires a prescription from your veterinary surgeon. click here

Comfortis chewable tablets are an antiparasitic tablet designed for dogs and cats. They can be used to treat and prevent flea infestations, as well as help manage FAD (flea allergy dermatitis). Suitable for dogs weighing 2.1-3kg and cats weighing 1.9-2.8kg.

Brand

Comfortis

Manufacturer

Elanco

Species

Cat, Dog

Prescription Type

POM-V (Written prescription required)

Be the first to review this product

£36.89
Reference : Med-8118020
Delivery Between 2 and 3 days
  • Description
  • Properties
  • Packaging
  • Ingredients
  • Directions
  • Legal notice
  • Customer Reviews
  • Further advice

Comfortis chewable tablets are an antiparasitic tablet designed for dogs and cats. They can be used to treat and prevent flea infestations, as well as help manage FAD (flea allergy dermatitis). Suitable for dogs weighing 2.1 - 3kg and cats weighing 1.9-2.8kg.


Indications for use
Treatment and prevention of flea infestations (Ctenocephalides felis).
The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).


Prescription only medicine.
Comfortis Chewable Tablets are only available with a prescription from your veterinary surgeon.
To check the most up to date information about this product, please read its Summary of Product Characteristics (SPC) below:
http://www.vmd.defra.gov.uk/ProductInformationDatabase/Default.aspx

Spinosad comprises spinosyn A and spinosyn D. The insecticidal activity of spinosad is characterised by nervous excitation leading to muscle contractions and tremors, prostration, paralysis and rapid death of the flea. These effects are caused primarily by activation of nicotinic acetylcholine receptors (nAChRs). Spinosad therefore has a different mode of action to other flea control or insect control products. It does not interact with known binding sites of other nicotinic or GABAergic insecticides such as neonicotinides (imidacloprid or nitenpyram), fiproles (fipronil), milbemycins, avermectins (e.g. selamectin) or cyclodienes, but through a novel insecticidal mechanism.

 

The product starts killing fleas 30 minutes after administration; 100% of fleas are dead/moribund within 4 hours post-treatment in dogs, and in cats within 24 hours.

 

Insecticidal activity against new infestations persists for up to 4 weeks.

6 tablets

Active substance:
Spinosad 140 mg

Comfortis is a prescription product and must be applied according to the instructions of your veterinary surgeon.
Please read the product leaflet thoroughly before applying to your pet.

Marketing Authorisation Holder
Eli Lilly and Company Ltd
Elanco Animal Health
Priestley Road
Basingstoke
Hampshire
RG24 9NL
UNITED KINGDOM

 

Marketing Authorisation Number
EU/2/10/115/018

Contraindications

  • Do not use in dogs or cats under 14 weeks of age.
  • Do not use in case of known hypersensitivity to the active substance or to any of the excipients.
  • Special warnings for each target species
  • The veterinary medicinal product should be administered with food or immediately after feeding. The duration of efficacy may be reduced if the dose is administered on an empty stomach.
  • All dogs and cats within the household should be treated.
    Fleas from pets often infest the animal’s basket, bedding and regular resting areas such as carpets and soft furnishings, which should be treated in case of massive infestation and at the beginning of the treatment with a suitable insecticide and vacuumed regularly.
  • Fleas may persist for a period of time after administration of the product due to the emergence of adult fleas from pupae already in the environment. Regular monthly treatments with Comfortis break the fleas’ life cycle and may be needed to control the flea population in contaminated households.

Special precautions for use in animals

  • Use with caution in dogs and cats with pre-existing epilepsy.
  • Accurate dosing is not possible in dogs weighing less than 1.3 kg and in cats weighing less than 1.2 kg. The use of the product in smaller dogs and smaller cats is therefore not recommended.
  • The recommended dosage regimen should be followed (see overdose section).

Special precautions to be taken by the person administering the veterinary medicinal product to animals

  • Accidental ingestion may cause adverse reactions.
  • Children should not come into contact with the veterinary medicinal product.
  • In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
  • Wash hands after use.

Adverse reactions (frequency and seriousness)

-          Dogs

  • In dogs, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 45–70 mg/kg bodyweight, the observed incidence of vomiting in the field trial was 5.6%, 4.2% and 3.6% after the first, second and third monthly treatments respectively. The incidence of vomiting observed after the first and second treatments was higher (8%) in dogs dosed at the upper end of the dose band. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
  • In dogs lethargy, anorexia and diarrhoea were uncommon and muscle tremor, ataxia and seizures were rare. In very rare cases, blindness, impaired vision and other eye disorders were observed.

-          Cats

  • In cats, a commonly observed adverse reaction is vomiting, which occurs in the first 48 hours after dosing and is most likely caused by a local effect on the small intestines. On the day of, or the day following administration of spinosad at a dose of 50–75 mg/kg bodyweight, the observed incidence of vomiting in the global field trial was between 6% and 11% in the first three months of treatment. In the majority of cases, vomiting was transient, mild and did not require symptomatic treatment.
  • Other commonly observed adverse reactions in cats were diarrhoea and anorexia. Lethargy, loss of condition and salivation were uncommon. Seizures were rare adverse reactions.

 

  • The frequency of adverse reactions is defined using the following convention:
    - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
    - common (more than 1 but less than 10 animals in 100 animals)
    - uncommon (more than 1 but less than 10 animals in 1,000 animals)
    - rare (more than 1 but less than 10 animals in 10,000 animals)
    - very rare (less than 1 animal in 10,000 animals, including isolated reports).

Use during pregnancy, lactation or lay

-          Pregnancy:

  • Laboratory studies in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects.
  • In pregnant dogs (bitches), the safety of spinosad has not been sufficiently established. The safety of spinosad in pregnant cats (queens) has not been evaluated.

-          Lactation:

  • In dogs, spinosad is excreted in the colostrum and milk of lactating bitches and it is therefore assumed that spinosad is excreted in the colostrum and milk of lactating queens. As the safety of this for suckling puppies and kittens has not been established, the product should only be used during pregnancy and lactation according to the benefit-risk assessment by the responsible veterinarian.

-          Fertility:

  • Laboratory studies in rats and rabbits have not produced any evidence of any effect on the reproductive capacity in males and females.
  • The safety of the product in male dogs and male cats used for breeding has not been determined.
  • Interaction with other medicinal products and other forms of interaction
    Spinosad has been shown to be a substrate for P-glycoprotein (PgP). Spinosad could therefore interact with other PgP-substrates (for example, digoxin, doxorubicin) and possibly enhance adverse reactions from such molecules or compromise efficacy.
  • Post marketing reports, following the concomitant use of Comfortis with ‘off label’ high dose ivermectin indicate that dogs have experienced trembling/twitching, seizures, ataxia, salivation/drooling, mydriasis, blindness and disorientation.